Congress Park Capital LLC Has $1.58 Million Stake in Zoetis Inc. (NYSE:ZTS)

Congress Park Capital LLC cut its stake in Zoetis Inc. (NYSE:ZTS) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,665 shares of the company’s stock after selling 425 shares during the quarter. Congress Park Capital LLC’s holdings in Zoetis were worth $1,575,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Darwin Wealth Management LLC bought a new stake in Zoetis during the third quarter worth $31,000. First Personal Financial Services purchased a new position in Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the 3rd quarter worth $33,000. Dunhill Financial LLC raised its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP raised its holdings in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after purchasing an additional 153 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 1.3 %

NYSE:ZTS opened at $169.30 on Friday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The stock’s fifty day moving average price is $171.25 and its two-hundred day moving average price is $180.07. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The company has a market cap of $76.38 billion, a P/E ratio of 31.82, a P/E/G ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the company posted $1.36 EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, analysts expect that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.18%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Stifel Nicolaus reduced their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. upped their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. UBS Group initiated coverage on Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Finally, Leerink Partners started coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.